RxDoctor Payments Data

Stephanie Talton Williamson, MD

Internal Medicine · Wesley Chapel, FLNPI 1962581157

Payments from drug & device makers

$1,293in general payments, 2019–2025

Across 35 payments — averaging $36.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$450
  • Lilly USA, LLC$224
  • AbbVie$202
  • Novartis$111
  • Abbott$110
  • Pfizer$94
  • plus $102 from 5 others

What the payments were for

  • Food & beverage$1,293100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk12$450
Lilly USA, LLC9$224
AbbVie2$202
Novartis1$111
Abbott4$110
Pfizer1$94
AstraZeneca2$35
Exact Sciences1$23
Nevro Corp.1$17
GSK1$14
Merck1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,293 in reported general payments places this provider in the 70th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$127,395
Medicare patients
236
Services billed
1,788

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide92$109,033
MounjaroTirzepatide42$62,393
JanuviaSitagliptin Phosphate29$37,485
TrulicityDulaglutide15$31,236
JanumetSitagliptin Phos/Metformin Hcl29$26,203
FarxigaDapagliflozin Propanediol16$21,796
XareltoRivaroxaban24$20,313
JardianceEmpagliflozin13$19,677
EliquisApixaban15$12,287
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$3,470
Lantus SolostarInsulin Glargine,hum.Rec.Anlog35$3,158
Levothyroxine Sodium269$2,848
SynthroidLevothyroxine Sodium31$2,216
Fluticasone Propionate128$1,927
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$1,869

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$450$109,03392 claims
Lilly USA, LLCMounjaro, Trulicity$224$93,62957 claims
MerckJanuvia, Janumet$13$63,68858 claims
AstraZenecaFarxiga$35$21,79616 claims
PfizerEliquis$94$12,28715 claims
AbbVieSynthroid$202$2,21631 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Wesley Chapel

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →